Compass Therapeutics Inc. (CMPX)
1.71
-0.53 (-23.66%)
At close: Apr 02, 2025, 3:59 PM
1.57
-7.92%
After-hours: Apr 02, 2025, 07:54 PM EDT
-23.66% (1D)
| Bid | 1.57 |
| Market Cap | 235.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -4.74 |
| Forward PE | -8.44 |
| Analyst | Buy |
| Ask | 1.57 |
| Volume | 5,186,790 |
| Avg. Volume (20D) | 1,950,076 |
| Open | 2.28 |
| Previous Close | 2.24 |
| Day's Range | 1.69 - 2.44 |
| 52-Week Range | 0.77 - 4.08 |
| Beta | 1.00 |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascular...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 5, 2021
Employees 35
Stock Exchange NASDAQ
Ticker Symbol CMPX
Analyst Forecast
According to 8 analyst ratings, the average rating for CMPX stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 369.21% from the latest price.
Stock Forecasts2 days ago
+17.89%
Compass Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
1 month ago
+6.51%
Compass Therapeutics shares are trading higher after Guggenhiem initiated coverage on the stock with a Buy rating and announced a price target of $12.
